Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis.

Ramos TL, Sánchez-Abarca LI, Rosón-Burgo B, Redondo A, Rico A, Preciado S, Ortega R, Rodríguez C, Muntión S, Hernández-Hernández Á, De Las Rivas J, González M, González Porras JR, Del Cañizo C, Sánchez-Guijo F.

PLoS One. 2017 Aug 10;12(8):e0182470. doi: 10.1371/journal.pone.0182470. eCollection 2017.

2.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

3.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.

Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD).

Am J Hematol. 2017 Sep;92(9):E534-E541. doi: 10.1002/ajh.24813. Epub 2017 Jul 19.

PMID:
28612357
4.

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?

Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F.

Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969.

5.

Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling.

Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J.

BMC Genomics. 2016 Nov 21;17(1):944.

6.

Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.

Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, San Segundo L, Inogés S, Santos-Briz Á, García-Briñón J, Corchete LA, San Miguel JF, Del Cañizo C, Blanco B.

J Hematol Oncol. 2016 Oct 20;9(1):113.

7.

Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor.

Valencia J, Blanco B, Yáñez R, Vázquez M, Herrero Sánchez C, Fernández-García M, Rodríguez Serrano C, Pescador D, Blanco JF, Hernando-Rodríguez M, Sánchez-Guijo F, Lamana ML, Segovia JC, Vicente Á, Del Cañizo C, Zapata AG.

Cytotherapy. 2016 Oct;18(10):1297-311. doi: 10.1016/j.jcyt.2016.07.006.

PMID:
27637760
8.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P.

J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.

PMID:
27354480
9.

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, Insunza A, Barragán E, Del Rey M, García-Ruiz de Morales JM, Tormo M, Salido E, Zamora L, Pedro C, Sánchez-Del-Real J, Díez-Campelo M, Del Cañizo C, Sanz GF, Hernández-Rivas JM; Spanish Group for Myelodysplastic Syndromes (GESMD).

Oncotarget. 2016 May 24;7(21):30492-503. doi: 10.18632/oncotarget.9026.

10.

Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on NK cells: implications in the transplantation setting.

Blanco B, Herrero-Sánchez MD, Rodríguez-Serrano C, García-Martínez ML, Blanco JF, Muntión S, García-Arranz M, Sánchez-Guijo F, Del Cañizo C.

Eur J Haematol. 2016 Dec;97(6):528-537. doi: 10.1111/ejh.12765. Epub 2016 Jun 1.

PMID:
27118602
11.

Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.

Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, San-Segundo L, Inogés S, Santos-Briz Á, García-Briñón J, SanMiguel JF, Del Cañizo C, Blanco B.

Br J Haematol. 2016 Jun;173(5):754-68. doi: 10.1111/bjh.13984. Epub 2016 Feb 23.

PMID:
26914848
12.

MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry.

L Ramos T, Sánchez-Abarca LI, Muntión S, Preciado S, Puig N, López-Ruano G, Hernández-Hernández Á, Redondo A, Ortega R, Rodríguez C, Sánchez-Guijo F, del Cañizo C.

Cell Commun Signal. 2016 Jan 12;14:2. doi: 10.1186/s12964-015-0124-8.

13.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, del Cañizo C, Vallespí T; Grupo Español de Síndromes Mielodisplásicos (GESMD).

Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20.

PMID:
26688236
14.

Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma.

Alonso S, Cabrero M, Caballero JC, Dávila J, de la Calle VG, López-Godino O, López-Corral L, Pérez E, Vázquez L, Corral R, Caballero D, Del Cañizo C, Mateos MV.

Clin Case Rep. 2015 Jun;3(6):370-5. doi: 10.1002/ccr3.231. Epub 2015 Apr 9.

15.

Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.

Ramos TL, Sánchez-Abarca LI, López-Ruano G, Muntión S, Preciado S, Hernández-Ruano M, Rosado B, de las Heras N, Chillón MC, Hernández-Hernández Á, González M, Sánchez-Guijo F, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):921-4. doi: 10.1016/j.leukres.2015.05.014. Epub 2015 Jun 11.

PMID:
26105049
16.

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome.

Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, Vazquez L, Caballero D, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):828-34. doi: 10.1016/j.leukres.2015.05.003. Epub 2015 May 14.

PMID:
26009156
17.

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology.

Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6.

PMID:
25943181
18.

Human Bone Marrow Stromal Cells Differentiate Into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice.

Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, Herrero C, Velasco A, Carrancio S, Caballero-Velázquez T, Rodríguez-Barbosa JI, Parrilla M, Del Cañizo C, San Miguel J, Aijón J, Pérez-Simón JA.

Cell Transplant. 2015;24(12):2423-33. doi: 10.3727/096368915X687480. Epub 2015 Feb 18.

PMID:
25695936
19.

Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design.

Castaño-Vinyals G, Aragonés N, Pérez-Gómez B, Martín V, Llorca J, Moreno V, Altzibar JM, Ardanaz E, de Sanjosé S, Jiménez-Moleón JJ, Tardón A, Alguacil J, Peiró R, Marcos-Gragera R, Navarro C, Pollán M, Kogevinas M; MCC-Spain Study Group.

Gac Sanit. 2015 Jul-Aug;29(4):308-15. doi: 10.1016/j.gaceta.2014.12.003. Epub 2015 Jan 19.

20.

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.

Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G; IRON-2 Study Group.

Ann Hematol. 2015 May;94(5):779-87. doi: 10.1007/s00277-014-2274-y. Epub 2014 Dec 18.

PMID:
25516455

Supplemental Content

Loading ...
Support Center